Bvf Inc/il is an investment fund managing more than $3.57 trillion ran by Mark Lampert. There are currently 59 companies in Mr. Lampert’s portfolio. The largest investments include Moonlake Immunotherapeutics and Revolution Medicines Inc, together worth $1.19 trillion.
As of 7th August 2024, Bvf Inc/il’s top holding is 21,751,284 shares of Moonlake Immunotherapeutics currently worth over $956 billion and making up 26.8% of the portfolio value.
In addition, the fund holds 5,981,212 shares of Revolution Medicines Inc worth $232 billion, whose value grew 44.7% in the past six months.
The third-largest holding is Kymera Therapeutics worth $154 billion and the next is Ionis Pharmaceuticals Inc worth $152 billion, with 3,186,376 shares owned.
Currently, Bvf Inc/il's portfolio is worth at least $3.57 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Bvf Inc/il office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Mark Lampert serves as the President at Bvf Inc/il.
In the most recent 13F filing, Bvf Inc/il revealed that it had opened a new position in
Axsome Therapeutics Inc and bought 955,000 shares worth $76.9 billion.
This means they effectively own approximately 0.1% of the company.
Axsome Therapeutics Inc makes up
4.6%
of the fund's Health Care sector allocation and has grown its share price by 18.4% in the past year.
The investment fund also strengthened its position in Ionis Pharmaceuticals Inc by buying
757,763 additional shares.
This makes their stake in Ionis Pharmaceuticals Inc total 3,186,376 shares worth $152 billion.
Ionis Pharmaceuticals Inc soared 17.6% in the past year.
On the other hand, there are companies that Bvf Inc/il is getting rid of from its portfolio.
Bvf Inc/il closed its position in Syndax Pharmaceuticals Inc on 14th August 2024.
It sold the previously owned 1,875,000 shares for $44.6 billion.
Mark Lampert also disclosed a decreased stake in Protagonist Therapeutics Inc by 0.1%.
This leaves the value of the investment at $115 billion and 3,319,290 shares.
The two most similar investment funds to Bvf Inc/il are Wilbanks Smith & Thomas Asset Management and Equity Investment Corp. They manage $3.57 trillion and $3.56 trillion respectively.
Bvf Inc/il’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 47.0% of
the total portfolio value.
The fund focuses on investments in the United States as
42.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
17% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $714 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Moonlake Immunotherapeutics |
No change
21,751,284
|
$956,403,957,000 | 26.81% |
| Revolution Medicines Inc |
No change
5,981,212
|
$232,130,838,000 | 6.51% |
| Kymera Therapeutics, Inc. |
No change
5,161,801
|
$154,079,760,000 | 4.32% |
| Ionis Pharmaceuticals Inc |
31.20%
3,186,376
|
$151,862,680,000 | 4.26% |
| Mirum Pharmaceuticals Inc |
No change
4,370,024
|
$149,411,121,000 | 4.19% |
| Gh Research Plc |
No change
10,400,158
|
$121,265,842,000 | 3.40% |
| Protagonist Therapeutics Inc |
11.63%
3,319,290
|
$115,013,399,000 | 3.22% |
| Cullinan Therapeutics Inc |
79.89%
5,750,683
|
$100,291,912,000 | 2.81% |
| Olema Pharmaceuticals, Inc. |
No change
9,135,893
|
$98,850,362,000 | 2.77% |
| Structure Therapeutics Inc |
206.00%
2,487,762
|
$97,694,414,000 | 2.74% |
| Xoma Corp Del |
No change
3,633,743
|
$86,083,372,000 | 2.41% |
| Kura Oncology Inc |
14.71%
4,082,037
|
$84,049,142,000 | 2.36% |
| 4d Molecular Therapeutics In |
No change
3,922,413
|
$82,331,449,000 | 2.31% |
| Axsome Therapeutics Inc |
Opened
955,000
|
$76,877,500,000 | 2.16% |
| Cg Oncology Inc |
28.32%
2,417,885
|
$76,332,629,000 | 2.14% |
| Merus N.V |
9.11%
1,279,049
|
$75,681,329,000 | 2.12% |
| AC Immune SA |
29.26%
18,834,936
|
$75,151,395,000 | 2.11% |
| Tyra Biosciences Inc |
No change
4,661,194
|
$74,532,492,000 | 2.09% |
| 89bio Inc |
87.00%
7,568,479
|
$60,623,517,000 | 1.70% |
| Celcuity Inc |
Opened
3,466,000
|
$56,773,080,000 | 1.59% |
| Third Harmonic Bio Inc |
No change
4,365,933
|
$56,757,129,000 | 1.59% |
| Agios Pharmaceuticals Inc |
Opened
1,190,107
|
$51,317,414,000 | 1.44% |
| Zymeworks Inc |
No change
5,870,000
|
$49,953,700,000 | 1.40% |
| Essa Pharma Inc |
No change
8,748,629
|
$46,017,788,000 | 1.29% |
| Syndax Pharmaceuticals Inc |
Closed
1,875,000
|
$44,625,000,000 | |
| IDEAYA Biosciences, Inc. |
No change
1,162,306
|
$40,808,564,000 | 1.14% |
| Galapagos NV |
15.79%
1,569,422
|
$38,890,277,000 | 1.09% |
| Annexon Inc |
No change
7,000,000
|
$34,300,000,000 | 0.96% |
| Repare Therapeutics Inc. |
No change
10,333,600
|
$34,100,880,000 | 0.96% |
| Foghorn Therapeutics Inc. |
Opened
5,302,000
|
$30,486,500,000 | 0.85% |
| Calliditas Therapeutics AB |
No change
750,000
|
$29,242,500,000 | 0.82% |
| Newamsterdam Pharma Company |
No change
1,521,948
|
$29,236,621,000 | 0.82% |
| Roivant Sciences Ltd |
No change
2,742,409
|
$28,987,263,000 | 0.81% |
| Engene Holdings Inc |
No change
2,251,037
|
$21,227,279,000 | 0.60% |
| Janux Therapeutics Inc |
84.88%
441,528
|
$18,495,608,000 | 0.52% |
| Tscan Therapeutics Inc |
No change
2,989,474
|
$17,488,423,000 | 0.49% |
| Eledon Pharmaceuticals, Inc. |
45.45%
6,293,282
|
$16,614,264,000 | 0.47% |
| Allakos Inc |
No change
16,552,417
|
$16,552,417,000 | 0.46% |
| Immunic, Inc. |
No change
8,902,972
|
$9,882,299,000 | 0.28% |
| Ikena Oncology Inc |
No change
4,769,164
|
$7,869,121,000 | 0.22% |
| Vigil Neuroscience Inc |
No change
1,813,633
|
$7,254,532,000 | 0.20% |
| Vistagen Therapeutics Inc. |
No change
2,000,000
|
$6,960,000,000 | 0.20% |
| CytomX Therapeutics Inc |
20.73%
5,228,461
|
$6,378,722,000 | 0.18% |
| Cidara Therapeutics Inc |
Closed
6,861,127
|
$6,312,237,000 | |
| Elevation Oncology Inc |
No change
2,312,200
|
$6,242,940,000 | 0.18% |
| Delcath Sys Inc |
Closed
1,202,067
|
$5,733,860,000 | |
| Verastem Inc |
No change
1,685,219
|
$5,021,953,000 | 0.14% |
| Cidara Therapeutics Inc |
Opened
343,055
|
$4,096,077,000 | 0.11% |
| Lexicon Pharmaceuticals Inc |
Closed
1,686,924
|
$4,048,618,000 | |
| An2 Therapeutics Inc |
Closed
1,239,470
|
$4,028,278,000 | |
| Kronos Bio, Inc. |
Closed
2,905,043
|
$3,776,556,000 | |
| Pieris Pharmaceuticals Inc |
Closed
20,609,863
|
$3,775,727,000 | |
| Verve Therapeutics Inc |
No change
650,000
|
$3,172,000,000 | 0.09% |
| Molecular Partners Ag |
No change
443,221
|
$3,169,030,000 | 0.09% |
| Ovid Therapeutics Inc |
No change
3,853,818
|
$2,964,357,000 | 0.08% |
| Sab Biotherapeutics Inc |
No change
917,826
|
$2,845,261,000 | 0.08% |
| GlycoMimetics Inc |
No change
9,544,262
|
$2,687,664,000 | 0.08% |
| Pieris Pharmaceuticals Inc |
Opened
257,626
|
$2,545,345,000 | 0.07% |
| Inventiva Sa |
No change
686,040
|
$2,023,818,000 | 0.06% |
| Viracta Therapeutics Inc |
No change
3,614,662
|
$1,965,292,000 | 0.06% |
| Forte Biosciences, Inc. |
No change
2,982,105
|
$1,601,390,000 | 0.04% |
| Nls Pharmaceutics Ltd |
No change
5,747,126
|
$1,246,552,000 | 0.03% |
| Unicycive Therapeutics Inc |
39.09%
2,200,000
|
$1,102,420,000 | 0.03% |
| Rezolute Inc |
No change
190,815
|
$820,505,000 | 0.02% |
| Corvus Pharmaceuticals Inc |
Closed
361,406
|
$643,303,000 | |
| Molecular Templates Inc |
No change
522,238
|
$600,574,000 | 0.02% |
| ASLAN Pharmaceuticals Ltd |
No change
1,049,999
|
$315,000,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 67 holdings | |||